amantadine has been researched along with Delirium in 12 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Delirium: A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine hydrochloride is a risky drug for triggering delirium in dialysis patients; however, it is often administered casually." | 8.31 | Amantadine-associated delirium in patients with maintenance dialysis: Insomnia-associated recovery and uneven seasonal distribution. ( Chao, J; He, J; Li, J; Si, B, 2023) |
| "We present three patients who, after long-term therapy with amantadine (4 to 18 years), experienced an acute delirium with confusion, disorientation, agitation, and paranoia on withdrawal." | 7.70 | Acute delirium after withdrawal of amantadine in Parkinson's disease. ( Brown, DL; Factor, SA; Molho, ES, 1998) |
| "In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 7.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
| " Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium." | 4.79 | Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. ( Camicioli, R; Ganzini, L; Young, BK, 1997) |
| "Amantadine hydrochloride is a risky drug for triggering delirium in dialysis patients; however, it is often administered casually." | 4.31 | Amantadine-associated delirium in patients with maintenance dialysis: Insomnia-associated recovery and uneven seasonal distribution. ( Chao, J; He, J; Li, J; Si, B, 2023) |
| "We pooled individual patient data of five single-centre observational studies to determine the effect of amantadine treatment among patients with ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, community-acquired bacterial meningitis and status epilepticus, admitted between January 2012 and December 2015 and ventilated ≥7 days." | 4.12 | Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury. ( Balk, S; Gerner, ST; Giede-Jeppe, A; Huttner, HB; Jäger, J; Kallmünzer, B; Kuramatsu, JB; Madzar, D; Mueller, T; Rühl, L; Schwab, S; Sembill, JA; Sprügel, MI, 2022) |
| "Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome." | 3.85 | The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. ( Fox, J; Fryml, LD; Pelic, CG; Revuelta, GJ; Robert, S; Sahlem, G; Short, EB; Williams, KR, 2017) |
| "We present three patients who, after long-term therapy with amantadine (4 to 18 years), experienced an acute delirium with confusion, disorientation, agitation, and paranoia on withdrawal." | 3.70 | Acute delirium after withdrawal of amantadine in Parkinson's disease. ( Brown, DL; Factor, SA; Molho, ES, 1998) |
| "In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 3.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Rühl, L | 1 |
| Kuramatsu, JB | 1 |
| Sembill, JA | 1 |
| Kallmünzer, B | 1 |
| Madzar, D | 1 |
| Gerner, ST | 1 |
| Giede-Jeppe, A | 1 |
| Balk, S | 1 |
| Mueller, T | 1 |
| Jäger, J | 1 |
| Schwab, S | 1 |
| Huttner, HB | 1 |
| Sprügel, MI | 1 |
| Li, J | 1 |
| Si, B | 1 |
| Chao, J | 1 |
| He, J | 1 |
| Fryml, LD | 1 |
| Williams, KR | 1 |
| Pelic, CG | 1 |
| Fox, J | 1 |
| Sahlem, G | 1 |
| Robert, S | 1 |
| Revuelta, GJ | 1 |
| Short, EB | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Moritoyo, T | 1 |
| Yabe, H | 1 |
| Nomoto, M | 1 |
| Young, BK | 1 |
| Camicioli, R | 1 |
| Ganzini, L | 1 |
| Factor, SA | 1 |
| Molho, ES | 1 |
| Brown, DL | 1 |
| Miyasaki, JM | 1 |
| Grimes, D | 1 |
| Lang, AE | 1 |
| Postma, JU | 1 |
| Van Tilburg, W | 1 |
| Rudorfer, MV | 1 |
| Manji, HK | 1 |
| Potter, WZ | 1 |
| Liberzon, I | 1 |
| Dequardo, JR | 1 |
| Silk, KR | 1 |
| Speeg, KV | 1 |
| Leighton, JA | 1 |
| Maldonado, AL | 1 |
| Herishanu, Y | 1 |
| Noah, Z | 1 |
1 review available for amantadine and Delirium
| Article | Year |
|---|---|
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic | 1997 |
11 other studies available for amantadine and Delirium
| Article | Year |
|---|---|
Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury.
Topics: Amantadine; Brain Injuries; Brain Ischemia; Consciousness; Delirium; Glasgow Coma Scale; Humans; Sei | 2022 |
Amantadine-associated delirium in patients with maintenance dialysis: Insomnia-associated recovery and uneven seasonal distribution.
Topics: Amantadine; Delirium; Humans; Renal Dialysis; Retrospective Studies; Seasons; Sleep Initiation and M | 2023 |
The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.
Topics: Aged; Amantadine; Catatonia; Delirium; Dopamine Agents; Electroconvulsive Therapy; Humans; Male; Mid | 2017 |
Plasma amantadine concentrations in patients with Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Creatinine; Delirium; Female; Hallucinations; Humans; | 2009 |
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Topics: Acute Disease; Age of Onset; Aged; Amantadine; Delirium; Female; Humans; Male; Parkinson Disease; Su | 1998 |
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Topics: Amantadine; Delirium; Humans; Parkinson Disease; Substance Withdrawal Syndrome | 1999 |
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
Topics: Aged; Amantadine; Benztropine; Biperiden; Delirium; Drug Eruptions; Female; Hallucinations; Humans; | 1975 |
Bupropion, ECT, and dopaminergic overdrive.
Topics: Aged; Amantadine; Antidepressive Agents; Bupropion; Combined Modality Therapy; Delirium; Drug Therap | 1991 |
Bupropion and delirium.
Topics: Aged; Amantadine; Antidepressive Agents; Bupropion; Delirium; Depressive Disorder; Drug Therapy, Com | 1990 |
Toxic delirium in a patient taking amantadine and trimethoprim-sulfamethoxazole.
Topics: Aged; Amantadine; Biological Transport; Delirium; Drug Interactions; Humans; Kidney; Male; Procainam | 1989 |
On acute encephalitic parkinsonian syndrome. Case report and review of the recent literature.
Topics: Amantadine; Child, Preschool; Delirium; Electroencephalography; Encephalitis, Arbovirus; Humans; Mal | 1973 |